Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy

Journal of Urology

Volumn 172, Issue 6 I, 2004, Pages 2193-2196

  De Vries, Stijn H ^a   Raaijmakers, René ^c   Kranse, Ries ^b   Blijenberg, Bert G ^a   Schroder F H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum Rotterdam   (Netherlands)

^c Erasmus Medical Center ^*

Author keywords

Adenocarcinoma; Mass screening; Patient selection; Prostate; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER THERAPY; CONTROLLED STUDY; DISEASE ACTIVITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT PLANNING;

EID: 6344239325     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000140958.31366.9f     Document Type: Article

References (21)

1. Roobol, M. J. and Schroder, F. H.: European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int, suppl., 92: 88, 2003
2. Eskew, L. A., Bare, R. L. and McCullough, D. L.: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol, 157: 199, 1997
3. Schroder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K. and Pavone-Macaluso, M.: The TNM classification of prostate cancer. Prostate, suppl., 4: 129, 1992
4. Hoedemaeker, R. F., Kranse, R., Rietbergen, J. B., Kruger, A. E., Schroder, F. H. and van der Kwast, T. H.: Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer, 85: 145, 1999
5. Charlson, M. E., Pompei, P., Ales, K. L. and MacKenzie, C. R.: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis, 40: 373, 1987
6. Passing, H. and Bablok, W.: A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I. J Clin Chem Clin Biochem, 21: 709, 1983
7. Yurdakul, G., Bangma, C. H., Blijenberg, B. G., van Zelst, B. D., Wildhagen, M. F., van der Kwast, T. H. et al: Different PSA assays lead to detection of prostate cancers with identical histological features. Eur Urol, 42: 154, 2002
8. Raaijmakers, R., Wildhagen, M. F., Ito, K., Paez, A., de Vries, S. H., Roobol, M. J. et al: Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology, 63: 316, 2004
9. Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A., Schroder, F. H. et al: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst, 95: 868, 2003
10. Auvinen, A., Maattanen, L., Stenman, U. H., Tammela, T., Rannikko, S., Aro, J. et al: Lead-time in prostate cancer screening (Finland). Cancer Causes Control, 13: 279, 2002
11. Carter, H. B., Walsh, P. C., Landis, P. and Epstein, J. I.: Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol, 167: 1231, 2002
12. Choo, R., Klotz, L., Danjoux, C., Morton, G. C., DeBoer, G., Szumacher, E. et al: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol, 167: 1664, 2002
13. Holmberg, L., Bill-Axelson, A., Helgesen, F., Salo, J. O., Folmerz, P., Haggman, M. et al: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med, 347: 781, 2002
14. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Cote, K., Loffredo, M., Schultz, D. et al: Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer, 95: 281, 2002
15. Peschel, R. E. and Colberg, J. W.: Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol, 4: 233, 2003
16. Kupelian, P. A., Elshaikh, M., Reddy, C. A., Zippe, C. and Klein, E. A.: Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol, 20: 3376, 2002
17. Etzioni, R., Penson, D. F., Legler, J. M., di Tommaso, D., Loer, R., Gann, P. H. et al: Overdiagnosis due to prostate-specific antigen screening: lessons from U. S. prostate cancer incidence trends. J Natl Cancer Inst, 94: 981, 2002
18. Epstein, J. I. and Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA, 271: 368, 1994
19. Schmid, H. P., McNeal, J. E. and Stamey, T. A.: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 71: 2031, 1993
20. Egawa, S., Matsumoto, K., Suyama, K., Iwamura, M., Kuwao, S. and Baba, S.: Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma. Cancer, 86: 463, 1999
21. Prestigiacomo, A. F. and Stamey, T. A.: Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. J Urol, 155: 1977, 1996